MedPoint Solutions Logo MedPoint Solutions | Next-Gen Oncology Education

Programs and Commentary

Programs

Biomarker Testing and Precision Care in PDAC

View Program →

Connecting PTEN Deficiency to Treatment for mHSPC

View Program →

Beyond Oncology

Navigating the Unexpected: Lifestyle Variables and Patient Safety with Once-Weekly Basal Insulin

View Program →

EPP and XLP: Evolving Therapeutics and Patient Needs

View Program →

On LinkedIn

LinkedIn Post · Nov 10, 2026

Beethoven composed some of his greatest music after he lost his hearing.

Read on LinkedIn →
LinkedIn Post · Oct 27, 2026

The CME grant proposal landed in my inbox like a subpoena.

Read on LinkedIn →
LinkedIn Post · Oct 23, 2026

📋 Oncology data overload? New study enrolling!

Read on LinkedIn →
LinkedIn Post · Oct 21, 2026

My research assistant just handed me a small novel: "Here's everything I found!"

Read on LinkedIn →
LinkedIn Post · Oct 20, 2026

I went shopping for a case of AI getting oncology wrong. My LLM delivered the Costco version.

Read on LinkedIn →
LinkedIn Post · Oct 19, 2026

Over 96% of med students use AI. 90% have personally caught it being wrong. Reassuring or apocalyptic? Depends on your risk tolerance.

Read on LinkedIn →
LinkedIn Post · Oct 16, 2026

My AI oncology news scraper is like a metal detector on the beach.

Read on LinkedIn →
LinkedIn Post · Oct 15, 2026

Yesterday's post was a swing and a miss.

Read on LinkedIn →
LinkedIn Post · Oct 14, 2026

It's ESMO season, and 10 of 12 Presidential abstracts report 'meeting primary endpoints.' Seven have declared a survival win, including the VOLGA trial now under priority review.

Read on LinkedIn →
LinkedIn Post · Oct 13, 2026

Every year, a certain breed of med-ed professional shows up to ASCO looking like they just heard about bispecific antibodies for the first time.

Read on LinkedIn →
LinkedIn Post · Oct 8, 2026

I don't let AI write my oncology CME slides. I let it argue with them.

Read on LinkedIn →
LinkedIn Post · Oct 8, 2026

Nice surprise to get a shout-out from OncoDaily. Thank you for including me in Voices!

Read on LinkedIn →
LinkedIn Post · Oct 7, 2026

My junior medical editor just 'corrected' me by quoting data out of context.

Read on LinkedIn →
LinkedIn Post · Oct 6, 2026

It's tempting to blame the tool. But after my last CME project, I asked my AI assistant for feedback on how I work. Turns out it had notes.

Read on LinkedIn →
LinkedIn Post · Oct 5, 2026

What happens if you hand an AI a stack of recent EGFR-mutant NSCLC abstracts and ask for a CME deck?

Read on LinkedIn →
LinkedIn Post · Aug 5, 2026

Did you catch the new Pluvicto label? mHSPC & mCRPC → mAPMN/S & mAPMR.

Read on LinkedIn →
LinkedIn Post · Aug 4, 2026

Yesterday's question was which triplet for PSMA+ mHSPC. Today's is which patient.

Read on LinkedIn →
LinkedIn Post · Aug 3, 2026

In PSMA+ mHSPC, Pluvicto triplet or chemo triplet first?

Read on LinkedIn →
LinkedIn Post · Jul 30, 2026

Rash is a key daraxonrasib toxicity despite recommended upfront tetracycline + topical steroid (adherence not specified).

Read on LinkedIn →
LinkedIn Post · Jul 28, 2026

With 2L daraxonrasib doubling mOS vs chemo for mPDAC in RASolute 302 (now under FDA review), focus is already shifting towards 1L (RASolute 303) and even adjuvant use (RASolute 304).

Read on LinkedIn →